Healthcare
Tristel PLC(TSNLF)
Live Price
Offline$5.53
+0.00% today
1Y Change
+4.54%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +10.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 3.5%
Coverage: 255 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tristel PLC (TSNLF) is a Healthcare stock with a market cap of $190.00M and listed on OTC. The stock last traded around $5.53 and up 4.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +10.8%, EPS growth of 0.0%, a dividend yield of 3.5%. What stands out right now is revenue +10.8%, EPS 0.0%, free cash flow +8.7% with operating margin 19.7% and ROIC 19.7%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 24.6 and price/sales 3.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines TSNLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.8% vs +7.6% peer median
Operating Margin
Near sector median
+19.7% vs +19.4% peer median
P/E
Below sector median
24.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Mar 2, 2026 with an EPS surprise of +2.0% and a revenue surprise of -0.6%.
The setup is mixed rather than one-directional
Revenue is +10.8% and EPS is 0.0%, while operating margin sits near 19.7%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 19, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 2, 2026 | +2.0% | +0.0% | +0.0% | -16.7% |
2025 Feb 24, 2025 | โ | +0.0% | +0.0% | +0.0% |
2024 Oct 21, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSNLF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TSNLF Max Drawdown
-16.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TSNLF and SPY.
Company Overview
Tristel PLC
Other OTC
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
- Leadership
- Matthew Giovanni Sassone
- IPO Date
- Jul 17, 2014
- Employees
- 233
- Street Address
- Lynx Business Park
- Mailing
- Snailwell
- Region
- Snailwell, GB
- Reporting Currency
- USD
- Investor Line
- +44 1638 721500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.6
- EV/EBITDA
- 15.4
- Price/Sales
- 3.9
- Price/Book
- 5.8
Growth
- Revenue
- +10.8%
- EPS
- 0.0%
- Free Cash Flow
- +8.7%
Profitability
- Gross Margin
- 78.7%
- Operating Margin
- 19.7%
- Net Margin
- 15.9%
- ROE
- 23.6%
- ROIC
- 19.7%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 4.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.